Biological drugs in the treatment of atopic diseases in pediatric patients

The complexity of the treatment of atopic diseases, including bronchial asthma, atopic dermatitis, and chronic urticaria, in pediatric patients lies in the detrimental effect of first-line drugs (glucocorticoids) on children's health and in the low prevalence of types of biological preparations due to limited data on their efficacy and safety, especially for the child population. The work presents a review of data on therapy with biological preparations in various pathological conditions, their effectiveness and safety in the long term. The aim of the review is to summarize the data on the treatment of atopic diseases with biological preparations. Materials and methods. We identified putatively relevant studies by searching MEDLINE, SCOPUS, PubMed, and Google Scholar electronic databases over the past 7 years using the terms: bronchial asthma; chronic urticaria; atopic dermatitis; biological preparations; omalizumab; dupilumab; mepolizumab; safety; monoclonal antibodies; efficiency. Further, according to the inclusion and exclusion criteria, as well as the independent selection of all authors, the suitable sources were selected and the review was compiled. Results. At the moment, there are not enough long-term studies on this topic, especially in pediatric practice. However, the existing ones allow drawing a preliminary conclusion about the prospects for further study of this topic in the treatment of atopic diseases.

• Publication year

  2023

• Venue

  Glavvrač (Chief Medical Officer)

• Publication date

  2023-03-15

• Fields of study

  Not labeled

• Identifiers
  DOI 10.33920/med-03-2303-02
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)

  2022cited by this paper
• Airway autoimmunity, asthma exacerbations, and response to biologics

  2022cited by this paper
• Current and emerging biologic therapies targeting eosinophilic disorders

  2022cited by this paper
• Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China.

  2021cited by this paper
• A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

  2020cited by this paper
• Эффективность омализумаба в сочетании со стандартной терапией в сравнении со стандартной терапией без омализумаба у детей с хронической спонтанной крапивницей: 36-месячное сравнительное наблюдательное исследование

  2020cited by this paper
• Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta‐analysis

  2020cited by this paper
• Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi‐center retrospective case series

  2020cited by this paper
• Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

  2020cited by this paper
• Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.

  2020cited by this paper
• Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.

  2020cited by this paper
• Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis

  2020cited by this paper
• Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

  2020cited by this paper
• Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

  2019cited by this paper
• Atopic March: Collegium Internationale Allergologicum Update 2020

  2019cited by this paper
• Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

  2019cited by this paper
• Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

  2019cited by this paper
• 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up.

  2019cited by this paper
• Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.

  2019cited by this paper
• Urticaria and Angioedema: an Update on Classification and Pathogenesis

  2018cited by this paper
• Biological therapy of asthma: present and future

  2018cited by this paper
• Dupilumab: First Global Approval

  2017cited by this paper
• Real-life long-term omalizumab therapy in children with severe allergic asthma

  2015cited by this paper
• The discovery and development of omalizumab for the treatment of asthma

  2015cited by this paper
• Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

  2015cited by this paper
• Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization

  2013cited by this paper
• Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma

  2010cited by this paper
• IL-5- and eosinophil-mediated inflammation: from discovery to therapy.

  2009cited by this paper
• Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge.

  2005cited by this paper

• No citing papers are available for this paper.